Personalized Nursing Services Societe Anonyme Overview
UCare Services Belgique (formerly Personalized Nursing Services) is a founder-led micro-cap home-healthcare provider operating in French-speaking Belgium, principally the Mons-Borinage area of Hainaut, with historical activity in Brussels and Wallonia more broadly. It delivers nurse-led care at patients' homes (general nursing, palliative care, hygiene care, blood and urine sampling, peritoneal dialysis, stoma therapy, hospitalisation-at-home), provides nursing teams inside residential centres for people with disabilities and other institutions, and sells or rents medical equipment such as beds, incontinence products and pressure-sore prevention material. Revenue is overwhelmingly reimbursed care-act income tied to the Belgian INAMI/RIZIV nomenclature, plus institutional service contracts. Revenue peaked near €4.3M around 2009, stabilised at €2.5-3.0M during 2019-2023, then fell 34% to €1.75M in FY2024 with a €0.68M net loss. The shares, once the only listed company in Mons-Borinage, now trade nominally, with the instrument flagged inactive.
What the company does
UCare Services Belgique is a provider of nursing care services outside the hospital. Its activity has historically been organised around three pillars, as summarised consistently by MarketScreener, Zonebourse and Boursorama:
-
Home medical assistance services — nursing acts at the patient's home, notably palliative care, blood sampling, peritoneal dialysis and stoma therapy (and, historically, physiotherapy/kinesitherapy).
-
Care services in residential centres — the provision of nursing teams to institutions housing people with disabilities and other residential care facilities.
-
Equipment leasing and sales — incontinence protection, medical beds, pressure-sore (escarre) prevention material and related supplies.
A more recent description (FinancialFilings) presents the offer as four branded divisions: "Ucare at Home" (home care), "Ucare Inside" (services inside hospitals and residential centres), "Ucare City" (health-centre operations) and "Ucare Furnitures" (sale and rental of medical equipment), with a 24/7 service model across French-speaking Belgium since 2003. Investing.com's profile extends the service list to general nursing, personal hygiene care, blood and urine analysis, physiotherapy and rehabilitation, peritoneal dialysis, haemodialysis, stoma therapy and hospitalisation at home.
The company's own description
On its investor page, CEO and managing director Nicola d'Aniello describes a company that has "always been in motion"; he credits the 2014 integration into the UCare Services franchise network with renewing the business while preserving the founding-nurse vision, says the company built a broad range of services over fifteen years for growing demand both at home and in institutions, and states that a mobile application rolled out in 2019 would make UCare a major actor of the "home healthcare revolution," with a return to profitable, sustainable growth targeted from 2019 (company website, undated message, c.2019). The website's operational counters claim 365-day operation, 5,000+ satisfied patients, 750+ care acts per day, 99 staff members and 25+ transports per day (company website, undated; likely c.2019-2020 vintage).
Business and revenue model
| Revenue stream | Nature | Payer | Indicative weight | Source / basis |
|---|---|---|---|---|
| Home nursing acts | Fee-per-act / per-day forfaits under the Belgian INAMI/RIZIV nomenclature for nursing care | Mutualités (sickness funds) via third-party payer system; patient co-payment | Dominant (76% of revenue in 2008 from nursing; 84% nursing vs 16% physiotherapy in 2011) | L'Echo 25 Apr 2009; PNS press release 30 Mar 2012 |
| Institutional nursing | Contracted nursing teams for residential centres / institutes | Institutions (often publicly funded) | Material; three residential contracts terminated in Q4 2011; Ciney contract ramp-up from Oct 2011 | FY2011 annual report; press release 30 Mar 2012 |
| Physiotherapy (CML subsidiary) | Kinesitherapy acts | Sickness funds / patients | 16% of 2011 revenue (€0.583M); restructured 2010-2012; current status n/d | Press release 30 Mar 2012 |
| Equipment sales and rental | Product resale and rental | Patients, institutions | Minor ("third pillar," L'Echo 2009) | L'Echo 7 Jul 2009 |
| Health-centre operations ("Ucare City") | Primary-care centre | Sickness funds / patients | — | FinancialFilings |
Independent characterisation: the model is service-based, labour-intensive and reimbursement-dependent, with no subscription or licensing component. Gross margin is driven by the spread between nomenclature fees and nurse labour cost (employees, interim agency staff and independent nurses). Management repeatedly identified nurse recruitment as the binding constraint on growth (FY2011 CEO commentary) and automatic wage indexation as the main margin risk (L'Echo, 25 Apr 2009 and 14 Oct 2008).
Value-chain position, customers and end-markets
The company sits at the point of care: it is the last link between prescribing physicians (general practitioners and hospital specialists), hospitals discharging patients, and the patient's home or institution. Customer types are (i) individual patients (often elderly, chronically ill, palliative or post-discharge), (ii) prescribing doctors and hospitals as referral sources, and (iii) residential institutions purchasing nursing capacity. End-markets: Belgian home nursing, institutional nursing for disabled persons, and home medical equipment. The geographic market is French-speaking Belgium, chiefly Hainaut (Mons, Borinage, La Louvière) and historically Walloon Brabant (Waterloo) and Namur province (Ciney).
Strategy
Stated strategy (themes from company communications)
The only articulated strategic statement is the CEO message on the investor page (c.2019), whose themes are: (i) continuous renewal through the UCare Services franchise network (joined 2014); (ii) a broad service range spanning home and institutional care; (iii) digital patient connectivity via a mobile app rolled out in 2019, positioning UCare in the "home healthcare revolution"; and (iv) a return to profitable and sustainable growth from 2019, supported by loyal shareholders. Earlier, management emphasised profitability preservation as the main objective (FY2011 report), recruitment of nursing staff via interim agencies, and new institutional collaborations.
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| None verified | — | No company press releases, investor-day material or strategy updates have been published in this window. The only disclosure is the FY2024 results data point (Aug 2025). | — |
| Rede D'Or partnership, BNDES funding round, "UCare AI" launch | Claimed mid/Q3/Oct 2025 | Reported only by roic.ai; uncorroborated and inconsistent with company scale and geography | — |
Historical strategic initiatives (for context)
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Equipment sales as third pillar | Jul 2009 | Develop sale of medical material alongside nursing and physiotherapy | L'Echo 7 Jul 2009 |
| CML restructuring | 2010-2012 | Turnaround of physiotherapy subsidiary; relocation to La Louvière; target breakeven 2012-2013 | Press release 30 Mar 2012 |
| Initialis site, Mons | 2,012 | Establish PNS on Mons science park | Press release 30 Mar 2012 |
| Ciney institutional ramp-up | 2011-2012 | Scale from 24 to target 230 patients | Press release 30 Mar 2012 |
| UCare franchise integration | 2,014 | Rebranding and network membership | Company website |
| Name change to UCare Services Belgique | Dec 2018 | Corporate rebrand | Company website |
| Mobile app | 2,019 | Patient app | Company website |
ESG commitments, cost programmes, medium-term targets
No ESG commitments, cost programmes with quantified targets, or medium-term financial guidance have been published since the 2008-2012 period (when the company issued revenue/profit forecasts and mentioned a possible revision of 2012-2014 objectives).
Products & Services
Flagship offerings: home nursing (the historical core, ≈76-84% of revenue when last disclosed) and institutional nursing. No product versions, technical specifications or list prices are published.
Product Portfolio
| Segment / brand | Service or product | Description and capabilities | Target customer | Launch / latest year | Pricing model | Source |
|---|---|---|---|---|---|---|
Ucare at Home | General nursing care | Injections, dressings, wound care, medication support | Home patients on prescription | Since 2003 | INAMI/RIZIV nomenclature fee per act | Euronext IPO summary; Investing.com |
Ucare at Home | Personal hygiene care ("toilettes") | Daily hygiene care for dependent patients | Elderly / dependent patients | Since 2003 | Nomenclature forfait | Euronext IPO summary |
Ucare at Home | Palliative care | End-of-life nursing at home | Palliative patients and families | Pre-2006 | Palliative nursing forfaits | Euronext IPO summary; MarketScreener |
Ucare at Home | Blood sampling and urine analysis | Home sample collection | Patients prescribed lab tests | Pre-2006 | Per act | Euronext IPO summary; Investing.com |
Ucare at Home | Peritoneal dialysis | Home-based dialysis support | Renal patients | Pre-2006 | Per act / forfait | Euronext IPO summary |
Ucare at Home | Haemodialysis support | Listed by Investing.com | Renal patients | — | — | Investing.com |
Ucare at Home | Stoma therapy | Ostomy care and education | Ostomy patients | Pre-2006 | Per act | Euronext IPO summary |
Ucare at Home | Hospitalisation at home | Post-acute care at home reducing length of stay | Hospital-discharged patients | — | — | Investing.com; FinancialFilings |
Ucare at Home / CML | Physiotherapy and rehabilitation | Kinesitherapy at home and in centres (CML subsidiary) | Rehab patients | c.2008; restructured 2010-2012 | Nomenclature | Press release 30 Mar 2012 |
Ucare Inside | Integrated care for disabled persons | Nursing teams in residential communities / institutes | Residential centres for handicapped people | Pre-2006 | Contract | Euronext IPO summary; FY2011 report |
Ucare City | Health centre | Primary-care centre operations | Local population | — | — | FinancialFilings |
Ucare Furnitures | Medical beds | Sale and rental | Home patients | Pillar developed 2009 | Sale / rental fee | L'Echo 7 Jul 2009; MarketScreener |
Ucare Furnitures | Incontinence protection | Product resale | Home patients, institutions | 2009 | Retail price | MarketScreener |
Ucare Furnitures | Pressure-sore prevention material | Mattresses / cushions etc. | Bedridden patients | 2009 | Sale / rental | MarketScreener |
Digital | UCare Services Belgique mobile app | Patient connectivity app | Patients | Announced for 2019 | — | Company website |
Logistics | Patient transport / supply delivery | "25+ transports per day" | Patients | — | — | Company website |
Financial Narrative
Important disclosure limitations. As a Marché Libre / Euronext Access issuer, the company is not required to publish IFRS financial statements, half-year reports or regulated information. The only verified five-year data are revenue (FY2019-FY2024) and net income (FY2023-FY2024) from S&P Capital IQ via MarketScreener. All other line items are not publicly disclosed in sources reviewed and are left blank.
Income statement: notes and sources
Sources: revenue FY2020-FY2023 MarketScreener/S&P Capital IQ; FY2024 revenue and FY2023-FY2024 net income from S&P Capital IQ results note (24 Aug 2025: sales €1.75M vs €2.66M; net loss €0.680738M vs €0.013585M). EPS calculated on 612,500 shares (no dilution disclosed). Dividends: last declared dividend was €0.10 for FY2016; no subsequent dividend notices found, so FY2023-FY2024 shown as 0 (inferred from absence of any coupon notice after coupon no. 10).
Long-run revenue history (context)
FY2008: guidance was €4.32M and actual revenue beat plan by 3% (L'Echo 12 Apr 2008 and 25 Apr 2009) — but the plan baseline is ambiguous, so the actual is left blank. FY2009 is implied from FY2010's -6.7% decline (calculated, approximate). FY2012-FY2018: n/d (only H1 2015 revenue of €2.381M, +7.3%, and pre-tax operating result of €0.258M are disclosed, per press release 11 Jan 2016).
Balance sheet
All n/d. Note: the FY2011 statutory accounts (Belgian GAAP) showed small items such as €5,000 of cash guarantees, €1,789.84 of inventories and €4,015.81 of capital subsidies, illustrating the very small balance sheet scale (FY2011 annual report).
Cash flow
Cash flow statements n/d. No buyback programme has ever been disclosed.
Ratios
All n/d: balance sheet and cash flow data unavailable: ### Commentary on trends, inflections and drivers
Phase 1 — growth to a 2008-2009 peak. Following the 2006 listing, PNS guided to strong growth, targeting €4.32M of revenue and €0.34M of net profit in 2008 (L'Echo, 12 April 2008). Revenue reached an implied ≈€4.28M in 2009. Profitability was then already sensitive to Belgian automatic wage indexation, which squeezed 2008 profits despite revenue beating plan (L'Echo, 25 April 2009).
Phase 2 — contraction and restructuring (2010-2012). Revenue fell 6.7% in 2010 to €3.99M (though profit rose) and a further 7.3% in 2011 to €3.699M. The physiotherapy subsidiary CML was the main drag, with revenue down 10.8% and a €0.122M restructuring charge; nursing also declined for the first time (-6.6%), hit by the termination of three residential contracts in Q4 2011. Management pinned recovery on the ramp-up of the Ciney institutional contract and on recruiting nurses through interim agencies (press release 30 March 2012).
Phase 3 — smaller but profitable (2013-2016). By H1 2015 the business was much smaller (€2.381M for the half — implying roughly €4.5-4.8M annualised only if seasonality is flat, which is inconsistent with later full-year figures; the H1 figure may include items such as gross "business volume" rather than revenue, so annualisation is not recommended) but profitable, with a pre-tax operating result of €0.258M and consecutive dividends of €0.10 (FY2013), €0.20 (FY2015) and €0.10 (FY2016). The 2014 move into the UCare franchise network coincided with this period.
Phase 4 — stagnation (2019-2023). Revenue oscillated in a narrow €2.53-2.97M band, peaking in FY2021 (€2.97M, likely helped by COVID-era home-care demand) before declining modestly in FY2022-FY2023. FY2023 was close to breakeven (net loss of €13.6K).
Phase 5 — sharp deterioration (FY2024). Revenue fell 34.2% to €1.75M and the net loss widened fifty-fold to €0.681M (net margin -38.9%). The FY2024 loss alone equals roughly 2.8× the company's market value at the last traded price. The reasons are not disclosed; plausible drivers (not confirmed by the company) include loss of one or more institutional contracts, nurse shortages limiting capacity, and the fixed-cost burden of a listed structure on a shrinking revenue base. The cumulative effect on equity cannot be assessed without the NBB-filed balance sheet, but a loss of this magnitude relative to the business's scale raises the question of whether Belgian Companies and Associations Code "alarm bell" provisions (net assets below half or a quarter of capital) may have become relevant — this is flagged as an analytical question, not a confirmed fact.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
Healthcare Facilities & Services revenue (EUR Mn) | 2.53 | 2.82 | 2.97 | 2.72 | 2.66 | 1.75 |
YoY growth (%) | — | 11.5 | 5.3 | -8.4 | -2.2 | -34.2 |
Share of total revenue (%) | 100 | 100 | 100 | 100 | 100 | 100 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2010 | FY2011 |
|---|---|---|
Group revenue (EUR Mn) | 3.99 | 3.699 |
Nursing (PNS) revenue share (%) | 84 | 84 |
Physiotherapy (CML) revenue (EUR Mn) | 0.653 | 0.583 |
Physiotherapy (CML) revenue share (%) | 16 | 16 |
Nursing revenue YoY (%) | — | -6.6 |
Physiotherapy revenue YoY (%) | — | -10.8 |
Division (Brand) Overview
| Division (brand) | Content | Revenue | Source |
|---|---|---|---|
Ucare at Home | Home nursing: general care, palliative, hygiene, sampling, dialysis, stoma therapy, hospitalisation at home | — | FinancialFilings; company site |
Ucare Inside | Nursing teams within hospitals and residential centres | — | FinancialFilings |
Ucare City | Health-centre operations | — | FinancialFilings |
Ucare Furnitures | Sale and rental of medical equipment | — | FinancialFilings; company site ("Vente et location de matériel") |
Ucare Job | Recruitment portal for nurses | Not a revenue line | Company site |
Income Statement and Margin Analysis (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 2.82 | 2.97 | 2.72 | 2.66 | 1.75 |
Revenue YoY growth (%) | 11.5 | 5.3 | -8.4 | -2.2 | -34.2 |
Net income (EUR Mn) | — | — | — | -0.014 | -0.681 |
EPS basic (EUR) | — | — | — | -0.022 | -1.111 |
EPS diluted (EUR) | — | — | — | -0.022 | -1.111 |
Dividend per share (EUR) | — | — | — | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2020 | FY2021 | FY2023 | FY2024 |
|---|---|---|---|---|
Net margin (%) | — | — | -0.5 | -38.9 |
CAGR measure | Value | Basis | — | — |
Revenue CAGR FY2019-FY2023 (4 yrs) | +1.3% | €2.53M → €2.66M | — | — |
Revenue CAGR FY2020-FY2024 (4 yrs) | -11.2% | €2.82M → €1.75M | — | — |
Revenue change from c.2009 peak to FY2024 | ≈ -59% | ≈€4.28M (implied from FY2010 €3.99M at -6.7%) → €1.75M | — | — |
Income Statement
| Metric | FY2009 | FY2010 | FY2011 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (EUR Mn) | 4.28 | 3.99 | 3.699 | 2.53 | 2.82 | 2.97 | 2.72 | 2.66 | 1.75 |
Financial Analysis
| Metric | FY2023 | FY2024 |
|---|---|---|
Dividends paid (EUR Mn) | 0 | 0 |
Share buybacks (EUR Mn) | 0 | 0 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
Belgium revenue (EUR Mn) | 2.53 | 2.82 | 2.97 | 2.72 | 2.66 | 1.75 |
Belgium YoY growth (%) | — | 11.5 | 5.3 | -8.4 | -2.2 | -34.2 |
Rest of world revenue (EUR Mn) | 0 | 0 | 0 | 0 | 0 | 0 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | €0.40 | Yahoo Finance; TradingView; Boursorama |
Date of last price change | 11 Aug 2023 (all-time low) | TradingView |
All-time high | €4.95 (2 Nov 2015) | TradingView |
Decline from all-time high | -91.9% | Calculated |
1-year performance (to Oct 2026) | 0% (no trading) | Calculated |
3-year performance | ≈0% (price unchanged since Aug 2023) | Calculated |
5-year performance | n/d (Oct 2021 price n/d) | — |
Shares outstanding | 612,500 | Boursorama |
Market capitalization | €0.245M | Calculated |
Trading status | Inactive instrument | MarketScreener; FMP |
Share Price
| Metric | 2011 | 2015 | 2023 |
|---|---|---|---|
Reference share price (EUR) | 2.50 | 4.95 | 0.40 |
Valuation Multiples
| Multiple | UCare (at €0.40, FY2024) | Note |
|---|---|---|
P/E | Not meaningful (loss) | EPS FY2024 -€1.11 |
P/Sales | 0.14x | €0.245M / €1.75M |
Per-Share Data
| Metric | FY2013 | FY2015 | FY2016 |
|---|---|---|---|
Gross dividend per share (EUR) | 0.10 | 0.20 | 0.10 |
Coupon Details
| Coupon | Fiscal year | Gross DPS | Approval | Payment |
|---|---|---|---|---|
No. 7 | FY2013 | €0.10 | AGM 27 Jun 2014 | Nov 2014 (ex 24 Nov 2014) |
No. 8 | Presumably FY2014 | — | — | — |
No. 9 | FY2015 | €0.20 | AGM 25 Jul 2016 | Dec 2016 (ex 19 Dec 2016) |
No. 10 | FY2016 | €0.10 | AGM 9 Nov 2017 | 2,018 |
FY2007 | FY2007 | Nil | — | — |
Capital Markets
| Item | Status |
|---|---|
Buyback authorisation | None disclosed |
Moody's / S&P / Fitch ratings | Not rated |
Bonds outstanding | None disclosed |
Analyst Conclusions
Management guidance and consensus
No guidance has been issued since the 2008-2012 forecasts and the CEO's c.2019 aspiration to return to profitable growth. There is no consensus estimate.
Bull case
-
Structural demand tailwind: ageing, chronic disease and shorter hospital stays expand demand for exactly the technical home-care acts (palliative, dialysis, stoma, hospitalisation at home) in which the company has two decades of experience.
-
Demonstrated ability to operate near breakeven: FY2023 produced a loss of only €13.6K on €2.66M of revenue, showing the cost base can be roughly matched to a €2.5-3.0M revenue run-rate if volumes recover.
-
Option value at a trivial valuation: at 0.14x FY2024 sales and €0.245M market value, any recovery of lost contracts, an asset sale of the patient base to a larger network, or a buy-out by the founder could crystallise value well above the last price.
Bear case
-
Revenue collapse and heavy losses: a 34% revenue fall and a €0.681M loss in FY2024 suggest the business lost critical volume; at this scale, recovery requires capital and nurses that the company may not have.
-
Governance and transparency deficit: a founder holding every senior role, no published annual reports, no AGM notices since 2022 and no FY2025 data leave minority shareholders with little visibility or protection.
-
Untradeable equity: the instrument has been inactive since August 2023; even if fundamental value exists, minority holders may have no exit, and delisting or corporate restructuring could leave them with little.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Filing of FY2025 statutory accounts with the NBB | Reveals equity position, debt, liquidity and whether losses continued |
| AGM convening notice and agenda | Possible alarm-bell procedure, capital measures, or delisting resolutions |
| Euronext notices on PNSB | Suspension, delisting or reactivation of trading |
| Belgian Official Gazette (Moniteur belge) publications | Changes to board, registered office, name, or any judicial reorganisation |
| Contract wins or losses with institutions | Main driver of revenue swings historically |
| Nurse staffing levels | Capacity constraint on revenue |
Concluding analyst verdict
UCare Services Belgique — the former Personalized Nursing Services — is best understood not as an investable growth story but as a small, founder-run Walloon home-nursing business that happens to retain a dormant stock-market quotation. Its strategic logic is sound in principle: Belgium's ageing population, the policy push toward ambulatory and home-based care, and chronic nurse shortages all make reliable home and institutional nursing valuable. The company also has genuine operating heritage, with technical competencies in palliative care, dialysis and stoma therapy and a track record of paying dividends as recently as FY2016.
The evidence of the last five years, however, is discouraging. Revenue stagnated around €2.5-3.0M from 2019 to 2023 and then fell by a third in FY2024 to €1.75M, producing a net loss of €0.68M — a margin of roughly -39% and a figure close to three times the company's entire market value at the last traded price. Management has offered no public explanation, no recovery plan and no guidance. Governance is concentrated in a single individual, investor communication has effectively stopped since the December 2022 AGM notice, and the shares have not traded since August 2023, with the instrument now flagged inactive by data vendors.
For institutional investors, the security is effectively uninvestable: it lacks liquidity, disclosure, coverage and any verifiable balance-sheet information. For existing minority holders, the key question is solvency and the treatment of minorities in any restructuring, sale or delisting — matters that can only be assessed once the FY2024 and FY2025 statutory accounts are retrieved from the National Bank of Belgium. Investors should also explicitly disregard uncorroborated aggregator claims of Brazilian partnerships, BNDES funding or AI product launches. Verdict: Not rated / avoid; monitor NBB filings and Euronext notices for solvency and delisting signals.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Since | Background | Education | Source |
|---|---|---|---|---|---|
Nicola d'Aniello | Founder; Chairman; CEO; Managing Director (administrateur délégué); investor relations | Founder 2003; CEO/Chair recorded from 18 Jul 2011 | Nurse by training; founded the company; director of PNS since its listing | Nursing qualification (institution n/d) | MarketScreener; company website; La Province 18 Aug 2011 |
Directors' Remuneration
| Governance attribute | Status |
|---|---|
Chair / CEO separation | No — combined in the founder |
Audit committee | n/d (not legally required for a non-regulated-market issuer of this size) |
Corporate governance code compliance | Belgian Corporate Governance Code applies to regulated-market issuers; not applicable to a Marché Libre listing |
Remuneration report | Not published |
Proxy statement equivalent | AGM convening notices only (published on company website 2015-2022) |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Nicola d'Aniello (founder) | n/d (likely controlling; not disclosed) | — |
Institutional holders (top 10) | None disclosed; no institutional ownership reported by data vendors | — |
Total shares | 612,500 | Boursorama |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Geography | Revenue | Relative positioning | Source |
|---|---|---|---|---|---|
Croix Jaune et Blanche (CJB) | Home nursing | Wallonia & Brussels | — | Large non-profit home-nursing federation; far greater scale and density | General industry knowledge; figures n/d |
ASD – Aide & Soins à Domicile (Solidaris network) | Home nursing and home help | Wallonia & Brussels | — | Mutual-linked network with integrated referral access | General industry knowledge; figures n/d |
Wit-Gele Kruis | Home nursing | Flanders | — | Dominant Flemish home-nursing provider; no direct geographic overlap | General industry knowledge; figures n/d |
i-mens | Home nursing and care | Flanders | — | Large Flemish non-profit; no direct overlap | General industry knowledge; figures n/d |
Independent self-employed nurses (thousands) | Home nursing | All Belgium | — | Fragmented, low-overhead competition in every commune | General industry knowledge |
Eurocept Homecare | Specialised medical homecare ("hospital to home") | Benelux | €288.9M | Specialist with 250+ nurses and pharma/hospital partnerships; far larger | Gimv portfolio page |
Hospital-at-home programmes of hospital networks (e.g., Hainaut hospital groups) | Hospitalisation at home | Hainaut | — | Vertically integrated with referral source | General industry knowledge |
Medical equipment retailers / bandagisteries and pharmacies | Equipment sale and rental | Wallonia | — | Specialist retail with broader ranges | General industry knowledge |
Residential and institutional care groups (e.g., LNA Santé, which operates in France, Belgium and Poland) | Institutional nursing (in-house staff substitutes for outsourcing) | Belgium (partly) | — | Large operators internalise nursing | Sustainability Reports profile of LNA Santé |
Interim healthcare staffing agencies | Institutional nursing supply | Belgium | — | Compete for both institutional contracts and nurses | General industry knowledge |
Peer Comparison FY2024
| Metric | UCare Services Belgique (FY2024) | Eurocept Homecare |
|---|---|---|
Revenue (EUR Mn) | 1.75 | 288.9 (period n/d) |
Revenue growth (%) | -34.2 | — |
Net margin (%) | -38.9 | — |
R&D intensity (%) | n/d (≈0) | — |
Employees | 32 | 335 |
Recent Developments
The 18-month window (April 2025 – October 2026) contains only one verifiable development.
Within the 18-month window
| Date | Event | Significance | Source |
|---|---|---|---|
| 24-25 Aug 2025 | FY2024 results: revenue €1.75M vs €2.66M; net loss €0.681M vs €0.014M | Revenue -34%; loss equal to ≈2.8× market cap; signals severe operational stress | S&P Capital IQ via MarketScreener |
| Oct 2026 (status at cut-off) | No FY2025 results located; instrument still flagged inactive; no AGM notice published on company website since Dec 2022 | Disclosure gap; possible delayed accounts | MarketScreener; company website |
Prior disclosures (context, outside the window)
| Date | Event | Significance | Source |
|---|---|---|---|
| 11 Aug 2023 | Last recorded price €0.40 (all-time low) | Market value ≈€0.245M | TradingView; FMP |
| 2 Dec 2022 | Notice of AGM of 21 Dec 2022 | Last shareholder communication on website | Company website |
| 15 Oct 2021 | Notice of AGM of 28 Oct 2021 | Routine | Company website |
| 7 Dec 2020 | Notice of AGM of 22 Dec 2020 | Routine (late AGM) | Company website |
| 12 Aug 2019 | Notice of AGM of 4 Oct 2019 at THG Group, Lasne | Routine | Company website |
| 2,019 | Mobile app rollout announced | Digital initiative | Company website |
| Dec 2018 | Renamed UCare Services Belgique | Corporate identity | Company website |
| 14 Nov 2018 | Notice of AGM of 28 Nov 2018 | Routine | Company website |
| 9 Jul 2018 | Dividend coupon no. 10 (€0.10 for FY2016) paid | Last dividend | Company website |
| 26 Oct 2017 | Notice of AGM of 9 Nov 2017 | Approved FY2016 dividend | Company website |
| 15 Dec 2016 | Dividend coupon no. 9 (€0.20 for FY2015), ex-date 19 Dec 2016 | Highest dividend | Company website |
| 11 Jan 2016 | H1 2015 results: €2.381M (+7.3%); pre-tax operating result €0.258M | Profitable phase | Company press release |
Aggregator claims not admitted to the register
| Claimed date | Claim | Reason excluded |
|---|---|---|
| Mid-2025 | Partnership with Rede D'Or São Luiz for 60 hospitals | No corroboration; Brazilian market; inconsistent with €1.75M Belgian business |
| Q3 2025 | BRL 150M funding round led by BNDES; Peru entry | No corroboration; would exceed company value by orders of magnitude |
| Oct 2025 | Launch of "UCare AI" nurse-matching service | No corroboration from company |



